Roche presents data for hemophilia A therapy ACE910

Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting. Results from the open-label phase I study, conducted by Chugai, showed once-weekly subcutaneous administration of ACE910 was well tolerated and possessed a promising efficacy profile in hemophilia A patients.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news